Boldenone Cypionate

Boldenone Cypionate is Boldenone — the same 1,2-dehydrotestosterone compound that forms the basis of Equipoise — attached to an eight-carbon cypionate ester instead of the standard eleven-carbon undecylenate ester. The active hormone is identical: a testosterone derivative with a C1-C2 double bond that reduces estrogenic conversion, lowers androgenicity (50 rating vs testosterone's 100), and preserves a strong anabolic signal (100 rating). The cypionate ester produces a terminal half-life of approximately 8-10 days — shorter than undecylenate's 14 days but longer than most other common esters, striking a balance between injection convenience and time-to-steady-state.

The mechanism of action mirrors Boldenone Undecylenate exactly. Boldenone binds the androgen receptor in skeletal muscle to promote protein synthesis and nitrogen retention, stimulates erythropoietin production to increase red blood cell mass and oxygen-carrying capacity, converts to estradiol at approximately half the rate of testosterone (via aromatase), and undergoes 5-alpha reduction to the weak androgen dihydroboldenone in androgen-sensitive tissues. The cypionate ester's somewhat shorter half-life means that stable serum concentrations are reached 1-2 weeks faster than with undecylenate, and clearance after cessation is correspondingly quicker.

Boldenone Cypionate offers the same lean gains, enhanced vascularity, increased endurance, and appetite stimulation that characterize Equipoise, with a moderately faster onset and somewhat shorter PCT waiting period. The quality of tissue accrued is identical — lean, dry, and durable, with minimal water retention. For researchers who have used and appreciated Equipoise but wished for a slightly faster pharmacokinetic profile, Boldenone Cypionate delivers exactly that without altering the core pharmacology.

This compound serves intermediate to advanced researchers pursuing the same applications as Equipoise: lean mass accrual over extended cycles, recomposition, and endurance enhancement. The faster onset and clearance compared to undecylenate make it a better choice for researchers running moderately shorter cycles (10-14 weeks vs the 14-20 weeks typically recommended for Equipoise) or those who want to minimize the gap between last injection and PCT commencement. It remains a poor fit for short cycles or researchers seeking rapid results — Boldenone is a slow-building compound regardless of ester.

Administration is once weekly, with the cypionate ester providing stable levels across a 7-day injection interval. Standard research doses are 300-600mg/week, identical to Equipoise dosing. PCT can begin approximately 2-3 weeks after the final injection — a meaningful improvement over the 4-6 week wait required after Boldenone Undecylenate. As with Equipoise, regular hematocrit monitoring is essential due to Boldenone's erythropoietic effects. Stack applications are the same as Equipoise: testosterone base always required, with Masteron or Primobolan for cutting phases, or nandrolone for mass phases where the combination of joint support and lean tissue is desired. # Novo Pharma — Oral Product Detail Page Descriptions

18 oral steroid and ancillary compounds. Full PDP copy for the flagship site (site-c).

> **Voice:** Clinical, authoritative, premium. The Ordinary-inspired. "Researchers" not "users." Mechanism-first, then practical guidance.